Claudin 12: A Potential Drug Target and Biomarker (G9069)

Target Name: CLDN12

NCBI ID: G9069

CLDN12

Claudin 12: A Potential Drug Target and Biomarker

CLDN12, or Claudin 12, is a protein that is expressed in the endothelial cells of the body. It is a member of the Claudin gene family, which is known for the production of tight junction proteins that help to maintain tissue barrier integrity. CLDN12 is one of several proteins that have been identified as potential drug targets or biomarkers for various diseases, including cancer.

The Claudin gene family has been identified as a potential therapeutic target for a number of diseases due to its involvement in the development of tight junction barriers. These barriers are essential for maintaining tissue homeostasis and can be disrupted by various factors, such as cancer growth, inflammation, and aging. By targeting the production and function of tight junction proteins, such as CLDN12, researchers have the potential to develop new treatments for a variety of diseases.

CLDN12 has been shown to be involved in the development and maintenance of tight junction barriers in various tissues, including the brain, liver, and blood vessels. It has been shown to play a role in the regulation of cell signaling pathways that are involved in tissue barrier function, as well as in the regulation of angiogenesis, or the formation of new blood vessels.

In addition to its role in tissue barrier function, CLDN12 has also been shown to be involved in the regulation of cellular processes that are important for cancer development. For example, studies have shown that CLDN12 can promote the growth and survival of cancer cells, and that it is involved in the development of resistance to chemotherapy.

Given its involvement in the regulation of tight junction barriers and its potential role in cancer development, CLDN12 is a promising target for drug development. Researchers have identified several potential drug compounds that can inhibit the activity of CLDN12, and these compounds have been shown to be effective in preclinical studies in treating a variety of diseases, including cancer.

One of the challenges in the development of CLDN12 as a drug target is its complex structure and the difficulty of predicting its function in a wide variety of biological processes. However, researchers are making progress in understanding the role of CLDN12 in various tissues and developing new approaches to its targeting.

In addition to its potential as a drug target, CLDN12 has also been identified as a potential biomarker for a variety of diseases. The tight junction barrier is a critical layer of tissue that helps to regulate the flow of nutrients, drugs, and other substances into the body. By measuring the expression and function of CLDN12 and other tight junction proteins, researchers have been able to identify new biomarkers for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, CLDN12 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in various biological processes and to develop effective treatments for those who are affected by these diseases.

Protein Name: Claudin 12

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets